Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (WO2011154895) SÉQUENCE POLYNUCLÉOTIDIQUE, PROCÉDÉS, COMPOSITION ET MÉTHODES ASSOCIÉS
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

We Claim:

1) A polynucleotide sequence set forth as SEQ ID NO: 1.

2) The sequence as claimed in claim 1, wherein the polynucleotide codes for Heat Shock Protein 90 (HSP90) of Trypanosoma evansi.

3) A process for inhibiting Heat Shock Protein 90 (HSP90) of Trypanosoma species or Plasmodium species by 17-allylamino-17-demethoxygeldanamycin (17-AAG), optionally along with at least one pharmaceutically acceptable excipient, said process comprising act of contacting said 17-AAG with the HSP90.

4) A process for inhibiting Heat Shock Protein 90 (HSP90) of Trypanosoma species by Geldanamycin, optionally along with at least one pharmaceutically acceptable excipient, said process comprising act of contacting said Geldanamycin with the HSP90.

5) The processes as claimed in claims 3 and 4, wherein the HSP90 is obtained from samples infected with said species; and wherein the samples are selected from a group comprising blood, serum, lymph, urine and plasma or any combination thereof.

6) The process as claimed in claim 5, wherein the HSP90 is contacted with the 17- AAG at a concentration ranging from about 20mg/kg to about 60mg/kg of body weight of subject from which the sample is derived.

7) The process as claimed in claim 4, wherein the Geldanamycin is at a concentration ranging from about 20 μΐ/mg to about 50 μΐ/mg of lysate of the protein.

8) A process for identifying inhibition of Heat Shock Protein 90 of Trypanosoma species by compounds selected from a group comprising Geldanamycin (GA) and 17-allylamino-17-demethoxygeldanamycin (17-AAG) optionally along with at least one pharmaceutically acceptable excipient, said process comprising acts of : a) isolating and amplifying sequence coding for the Trypanosoma evansi HSP 90 (TeHSP90) to obtain an amplicon;

b) cloning the amplicon into a vector to obtain recombinant TeHSP90 sequence; and

c) infecting subject with the recombinant TeHSP90 sequence followed by administering GA or 17AAG to identify said Trypanosoma HSP90 inhibition.

9) A process for identifying inhibition of Heat Shock Protein 90 of Plasmodium species by 17-allylamino-17-demethoxygeldanamycin (17-AAG), optionally along with at least one pharmaceutically acceptable excipient, said process comprising acts of :

a) isolating and amplifying sequence coding for the Plasmodium berghei HSP 90 (PbHSP90) to obtain an amplicon;

b) cloning the amplicon into a vector to obtain recombinant PbHSP90 sequence; and

c) infecting subject with the recombinant PbHSP90 sequence followed by administering 17AAG to identify said Plasmodium HSP90 inhibition.

10) The processes as claimed in claims 8 and 9, wherein the 17-AAG is administered intraperitoneally in the range of about 20mg/kg to about 60mg/kg of body weight of the subject, wherein the subject is mammal.

11) The process as claimed in claim 8, wherein the Geldanamycin is at a concentration ranging from about 20 μΐ/mg to about 50 μΐ/mg of lysate of the HSP90.

12) The process as claimed in claim 8, wherein survival rate of the subject is enhanced by 60% post administering of the 17-AAG.

13) The process as claimed in claim 9, wherein survival rate of the subject is enhanced by about 30% to about 50% post administering of the 17-AAG.

14) The processes as claimed in claims 8 and 9, wherein the Plasmodium species is Plasmodium berghei and the Trypanosoma species is Trypanosoma evansi.

15) The processes as claimed in claims 8 and 9, wherein the administering is carried out intraperitoneally.

16) A method of treating Malaria or Surra, said method comprising act of administering 17-allylamino-17-demethoxygeldanamycin (17-AAG) optionally along with at least one pharmaceutically acceptable excipient, to a subject in need thereof.

17) A method of treating Surra, said method comprising act of administering Geldanamycin, optionally along with at least one pharmaceutically acceptable excipient, to a subject in need thereof.

18) The methods as claimed in claims 16 and 17, wherein the administering inhibits Heat Shock Protein 90 (HSP90) of species causing the Malaria and the Surra; and wherein the subject is mammal.

19) The processes as claimed in claims 3, 4, 8 and 9, and the methods as claimed in claims 16 and 17, wherein the excipient is selected from a group comprising gums, granulating agents, binding agents, lubricating agents, disintegrating agents, sweetening agents, coloring agents, flavoring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifying agents, antistatic agents, and spheronization agents or any combination thereof.